Patient Education on Treatment With Immune Checkpoint Inhibitors for Advanced/Recurrent Endometrial Cancer

Video

Sharyn Lewin, MD, FACS, shares how she discusses side effects with patients receiving immune checkpoint inhibitors for advanced/recurrent endometrial cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Related Content
Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population.

Alpelisib Combo Does Not Extend PFS in High-Grade Serous Ovarian Cancer

Russ Conroy
August 15th 2025
Article
Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
August 15th 2025
Podcast
Oncologists explore the considerations of mirvetuximab soravtansine treatment in platinum-resistant ovarian cancer, highlighting its efficacy and the management of ocular AEs.

Highlighting Multidisciplinary Ovarian Cancer Care With Oncologists, Ophthalmologists, and Nurses

ONCOLOGY Staff
August 15th 2025
Article
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
August 15th 2025
Podcast
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.

FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer

Tim Cortese
August 15th 2025
Article
Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype

Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype

Roman Fabbricatore
August 15th 2025
Article